|
Disease Progression & Incidence Rates
|
|
Percentage of clinical patients who experience ADL episodes per year
|
70 % (45–90 %)
|
95 % (90–95 %)
|
[8, 10–17]
|
|
Frequency of ADL episodes for clinical patients (in absence of MDA)
|
2 (0–7) per year
|
4 (0–7) per year
|
[8, 10–17]
|
|
Average duration of an ADL episode
|
4 (1–9) days
|
4 (1–9) days
|
[8, 10–17]
|
|
Disability weight for symptomatic LF infection
|
0.11 (0.073–0.157)
|
0.11 (0.073–0.157)
|
[40]
|
|
Mean age of the benefit cohorts (years)
|
Cohort 1: 20 (30)
|
Cohort 1: 20 (30)
| |
|
Cohort 2: 20 (30)
|
Cohort 2: 20 (30)
|
|
Cohort 3: 30 (40)
|
Cohort 3: 30 (40)
|
|
Patient Medical Expenses and Treatment Seeking Behavior
|
|
Percentage of patients with ADL seeking treatment per episode
|
55 % (55–70 %)
|
55 % (55–70 %)
|
[8, 11, 14, 44, 46]
|
|
India 70 % (70–98 %)
|
(India 75 % (75–98 %))
|
|
Percentage of chronic disease patients seeking treatment
|
20 % (20–50 %)
|
30 % (30–55 %)
|
[9, 44, 45]
|
|
India: 50 % (41–80 %)
|
India 55 % (48–100 %)
|
|
Average patient medical expenses per ADL episode
|
+−20 % of baseline value
|
+−20 % of baseline value
|
[8, 11, 44–48]
|
|
Average patient medical expenses for chronic disease per year
|
+−20 % of baseline value
|
+−20 % of baseline value
|
[8, 11, 44–48]
|
|
Lost Productivity & Wages
|
|
Work days per year
|
300 (261–365) days
|
300 (261–365) days
| |
|
Percentage of work hours lost per day during an ADL episode
|
75 % (50–93 %)
|
75 % (50–93 %)
|
[12, 14, 16, 87]
|
|
Percentage of work hours lost due to chronic disease
|
15 % (9–24 %)
|
19 % (11–31 %)
|
[12, 43, 45, 46]
|
|
Discounting
|
|
Discount rate
|
3 % (0–6 %)
|
3 % (0–6 %)
|
[59]
|
|
Impact of Treatment
|
|
The reduction in transmission experienced by the treated population
|
Year 1: 50 % (35 %)
|
Year 1: 50 % (35 %)
|
[18]
|
|
Year 2: 75 % (53 %)
|
Year 2: 75 % (53 %)
|
|
Year 3: 88 % (62 %)
|
Year 3: 88 % (62 %)
|
|
Year 4: 94 % (66 %)
|
Year 4: 94 % (66 %)
|
|
Year 5 95 % (67 %)
|
Year 5 95 % (67 %)
|
|
Reduction in the frequency of ADL episodes by MDA
|
50 % (15–88 %)
|
50 % (15–88 %)
|
[33, 36, 37].
|
|
Percentage of chronic disease alleviated by MDA
|
10 % (0–90 %)
|
15 % (0–69 %)
|
[20, 30–35]
|
